Literature DB >> 334799

Chemotactic factor inactivators of human granulocytes.

J P Brozna, R M Senior, D L Kreutzer, P A Ward.   

Abstract

During phagocytosis, neutrophils release a variety of substances that include activators and inactivators of chemotactic factors. It is generally considered that these represent hydrolytic enzymes. Elastase and cathepsin G, major proteases released from lysosomal granules during phagocytosis, contain broad hydrolytic activity. This study examined granule elastase and cathepsin G for their role as inactivators of chemotactic factors. Elastase and cathepsin G were purified from human neutrophils by Trasylol-Sepharose and CM-cellulose chromatography. Small amounts (approximately equal to 3 microgram, 1 muM) of elastase and cathepsin G, comparable to quantities released by 10(6) neutrophils during phagocytosis, completely inactivated the C5 chemotactic factor generated in human serum. Larger concentrations were needed to inactivate the C3 chemotactic factor, and when the bacterial chemotactic factor from Escherichia coli was employed, five times more elastase or cathepsin G was ineffective against this chemotactic factor. Supernatant fluid from human neutrophils that had ingested complement-coated zymosan particles contained elastase and cathepsin G and had inactivator activity for both the C5 chemotactic fragment and the bacterial factor. A specific inhibitor of elastase largely abolished the inactivator activity in the phagocytic supernates that was directed against C5 factor but did not affect the inactivator activity for the bacterial factor. Similar results occurred in studies of granule lysates. These data indicate heterogeneity in the chemotactic factor inactivator activity released by phagocytosing neutrophils. The predominant inactivator activity of the C5 chemotactic fragment is attributable to elastase and cathepsin G.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334799      PMCID: PMC372484          DOI: 10.1172/JCI108887

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Lactic dehydrogenase activity in blood.

Authors:  F WROBLEWSKI; J S LADUE
Journal:  Proc Soc Exp Biol Med       Date:  1955-10

2.  Localization of chymotrypsin-like cationic protein, collagenase and elastase in azurophil granules of human neutrophilic polymorphonuclear leukocytes.

Authors:  K Ohlsson; I Olsson; K Spitznagel
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-03

3.  The supravital method in the study of the cytology of blood and marrow cells.

Authors:  J L SCHWIND
Journal:  Blood       Date:  1950-07       Impact factor: 22.113

4.  Tissue fractionation. Past and present.

Authors:  C De Duve
Journal:  J Cell Biol       Date:  1971-07       Impact factor: 10.539

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  An improvement in the Hummel chymotrypsin assay.

Authors:  S H Kang; M S Fuchs
Journal:  Anal Biochem       Date:  1973-07       Impact factor: 3.365

7.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

8.  Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor.

Authors:  K Ohlsson; H Tegner
Journal:  Scand J Clin Lab Invest       Date:  1976-09       Impact factor: 1.713

9.  Effects of granulocyte neutral proteases on complement components.

Authors:  U Johnson; K Ohlsson; I Olsson
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

10.  A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization.

Authors:  E J Goetzl; K F Austen
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  22 in total

1.  In vitro and in vivo production of chemotactic inhibitors by tumor cells.

Authors:  M C Cohen; J P Brozna; P A Ward
Journal:  Am J Pathol       Date:  1979-03       Impact factor: 4.307

2.  Immunopathology of the lung: a review.

Authors:  K J Johnson; W E Chapman; P A Ward
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

3.  Generation and characterization of a neutrophil-derived inhibitor of fibroblast chemotaxis.

Authors:  H Mensing; B M Czarnetzki
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

4.  Acute inflammatory pulmonary reactions induced by chemotactic factors.

Authors:  U Desai; D L Kreutzer; H Showell; C V Arroyave; P A Ward
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

5.  Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and for tumor cells.

Authors:  F W Orr; J Varani; D L Kreutzer; R M Senior; P A Ward
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

6.  The role of elastases in the development of emphysema.

Authors:  Charles Kuhn; Robert M Senior
Journal:  Lung       Date:  1978-12       Impact factor: 2.584

7.  C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation.

Authors:  T W Muhlfelder; J Niemetz; D Kreutzer; D Beebe; P A Ward; S I Rosenfeld
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

8.  Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.

Authors:  M Shingu; M Nobunaga
Journal:  Am J Pathol       Date:  1984-11       Impact factor: 4.307

9.  Plasma and synovial fluid levels of granulocytal elastase-alpha-1-protease inhibitor complex in patients with rheumatoid arthritis.

Authors:  K Kuramitsu; A Yoshida
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis.

Authors:  S E Goldblum; D E Van Epps; W P Reed
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.